Toronto Immune and Digestive Health Institute (TIDHI)(6.3 mi away)Contact
+23 other location
tumor necrosis factor
Disease activity and response to therapy in ulcerative colitis (UC) can be assessed by a
range of endpoints including symptoms, endoscopic mucosal activity, histological disease
activity, and biomarkers. This study aims to determine the optimal treatment target, which is
a research priority for the management of UC both to inform clinical practice and to help
inform regulatory endpoints and targets for drug development.
Participants with active UC will be randomized in a 2:3:5 ratio to 1 of 3 groups, each with a
different treatment target. Treatment targets will be defined as:
Group 1: corticosteroid-free symptomatic remission
Group 2: corticosteroid-free endoscopic + symptomatic remission
Group 3: corticosteroid-free histological + endoscopic + symptomatic remission
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.